68Ga-DOTATATE PET/BT görüntülemede somatostatin analogları ile tedavi normal hedef organların ve malign lezyonların alımında farklılık gösterir mi?

Abstract
 Objective: 
 Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor imaging has been widely recent years. However, there conflicting publications the literature, although guidelines for discontinuing use SSA before imaging. This study aims to investigate effect SSAs on imaging.
 Material and Method: We retrospectively analyzed 253 patients who underwent 68Ga-DOTATATE between 2018 2022. Among these patients, those with low grades (Grade 1 Grade 2) using were included study. SUVmax (maximum standard uptake volume) normal target organs, primary metastases highest each organ compared after treatment. Results: 28 (16 females; 12 males, age [mean±SD], 54.82±14.27, range 18-78) NET therapy Although was decreased values measured application liver spleen, it not statistically significant (p>0.05). There no difference tumors metastatic lesions liver, bone, lung, or lymph nodes (P> 0.05).
 Conclusion: In conclusion, drugs do need be discontinued treatment follow-up tumor analogs. addition, may help report interpretation by increasing intensity spleen.